Holly Sundberg Malek

Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort

David Rieger, Hannes Becker, Bianca Walter, Lorenz Dörner et autres

Background: Molecular profiling and subsequent discussions in the Molecular Tumor Board (MTB) within the network of Centers for Personalized Medicine (CPM) have expanded therapeutic options for neuro-oncology patients. Here, we present an update of our Tübingen MTB cohort in adult patients with …

de (code pays fourni par la source)

Retrieval Augmented Therapy Suggestion for Molecular Tumor Boards: Algorithmic Development and Validation Study

Eliza Berman, Holly Sundberg Malek, Michael Bitzer, Nisar P. Malek et autres

BACKGROUND: Molecular tumor boards (MTBs) require intensive manual investigation to generate optimal treatment recommendations for patients. Large language models (LLMs) can catalyze MTB recommendations, decrease human error, improve accessibility to care, and enhance the efficiency of precision oncology. OBJECTIVE: In this study, …

de (code pays fourni par la source)

Retrieval Augmented Therapy Suggestion for Molecular Tumor Boards: Algorithmic Development and Validation Study

Eliza Berman, Holly Sundberg Malek, Michael Bitzer, Nisar Peter Malek et autres

Retrieval Augmented Therapy Suggestion for Molecular Tumor Boards: Algorithmic Development and Validation Study (Preprint)

Eliza Berman, Holly Sundberg Malek, Michael Bitzer, Nisar P. Malek et autres

BACKGROUND Molecular tumor boards (MTBs) require intensive manual investigation to generate optimal treatment recommendations for patients. Large language models (LLMs) can catalyze MTB recommendations, decrease human error, improve accessibility to care, and enhance the efficiency of precision oncology. OBJECTIVE In this study, …

App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE)

Lorenz Dörner, Lucia Grosse, Felix Stange, Hanni Hille et autres

Abstract Background Biomarker-based therapies are increasingly used in cancer patients outside clinical trials. Systematic assessment of patient-reported outcomes (PRO) is warranted to take patients’ perspectives during biomarker-based therapies into consideration. We assessed the feasibility of an electronic PRO assessment via a smartphone …

de (code pays fourni par la source)

NCOG-29. THE NEURO-ONCOLOGY MAGNITUDE OF CLINICAL BENEFIT SCALE (NEURO-MCBS) AS A COMPREHENSIVE AND CLINICALLY RELEVANT ASSESSMENT TOOL TO DETERMINE CLINICAL BENEFIT FROM TARGETED THERAPIES IN CNS TUMORS

Sylvia Christine Kurz, Mirjam Renovanz, Johannes Rieger, Paula Bombach et autres

Abstract BACKGROUND Once first-line therapy options fail, there are no effective therapy options for most neuro-oncological conditions, including glioblastoma, gliomas, and brain metastases, thereby representing a high unmet clinical need. Novel targeted therapy options are often explored in small phase-I studies or …

de (code pays fourni par la source)

P22.03.A FEASIBILITY OF AND COMPLIANCE TO ELECTRONIC PATIENT-REPORTED OUTCOME ASSESSMENT IN THE MOLECULAR TUMOR BOARD IN (NEURO-)ONCOLOGICAL PATIENTS UNDER TARGETED THERAPY (TRACE)

Mirjam Renovanz, Felix Stange, Lutz Dörner, Paula Bombach et autres

Abstract BACKGROUND Comprehensive genomic profiling and biomarker-based therapies are increasingly used in clinical trials and in innovative health care systems including the center for personalized medicine network. Systematic assessments of patient-reported outcomes (PRO) are warranted to gain insight into the perspective of …

de (code pays fourni par la source)

Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Mirjam Renovanz, Sylvia Christine Kurz, Johannes Rieger, Bianca Walter et autres

Background: The clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular profiling and targeted therapy in adult patients with advanced tumors in the …

de (code pays fourni par la source)

THE MOLECULAR INTERACTION PATTERN OF LENVATINIB ENABLES INHIBITION OF WILD-TYPE OR KINASE-MUTATED FGFR2-DRIVEN CHOLANGIOCARCINOMA

Stephan Spahn, Fabian Kleinhenz, Ekaterina Shevchenko, Aaron Stahl et autres

Enclosed are the molecular dynamics simulations of drug–FGFR2 systems and the MM-GBSA raw data. The zip archives include the molecular dynamics trajectory files in Desmond Maestro format (*_trj; *-out.cms), the naming of zip archives is as following: Drug_Studied FGFR2 mutant. MM-GBSA raw …

de, fi (code pays fourni par la source)